Wait, we have a special offer for you! ✋

Get your exclusive discount now

YES, get the discount! No, I'd pay the full price
Global Ischemic Heart Disease (IHD) Drugs Market Report 2024

Ischemic Heart Disease (IHD) Drugs Global Market Report 2025 – By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents), By Disease Class (Angina Pectoris, Myocardial Infarction), By End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) – Market Size, Trends, And Global Forecast 2025-2034

Ischemic Heart Disease (IHD) Drugs Global Market Report 2025

Report Price : $4490.00 | Pages : 175 | Published : January 2025 | Delivery Time: 2-3 business days | Format : pdf

Purchase Options
Request a Sample
Request For Discount
Customise Your Report
Item added to cart!
Request For Proposal
Request For Regional Data
FAQs

Need assistance or more information before the purchase?

Enquire Before Buying
Ischemic Heart Disease (IHD) Drugs Global Market Report 2025

Proud Members Of

checkslacipN checkaoirsN checkscipN
Description Table Of Contents Tables & Figures Market Insights Related Reports

Ischemic Heart Disease (IHD) Drugs Market Definition

Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

The main types of drug classes included in ischemic heart disease (IHD) drugs are anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs are pharmacological agents that target and lower abnormal levels of lipids (such as cholesterol and triglycerides) in the bloodstream to reduce the risk of cardiovascular disease. These are used to treat various classes of disease, including angina pectoris and myocardial infarction, and are used by several end users, such as hospital pharmacies, retail pharmacies, and online pharmacies.

Ischemic Heart Disease (IHD) Drugs Market Segmentation

The ischemic heart disease (IHD) drugs market covered in this report is segmented –

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

Ischemic Heart Disease (IHD) Drugs Market Size and growth rate 2025 to 2029: Graph

Ischemic Heart Disease (IHD) Drugs Market Size 2025 And Growth Rate

The ischemic heart disease (IHD) drugs market size has grown strongly in recent years. It will grow from $6.36 billion in 2024 to $6.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies.

Ischemic Heart Disease (IHD) Drugs Market Growth Forecast

The ischemic heart disease (IHD) drugs market size is expected to see steady growth in the next few years. It will grow to $7.86 billion in 2029 at a compound annual growth rate (CAGR) of 4.0%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs.

Book your 30 minutes free consultation with our research experts

Contact Us

Ischemic Heart Disease (IHD) Drugs Market Driver: Rising Prevalence Of Obesity And Diabetes Fuels Expansion Of The Ischemic Heart Disease (IHD) Drugs Market

The growing prevalence of obesity and diabetes is expected to propel the growth of the ischemic heart disease (IHD) drugs market going forward. Diabetes is a long-term metabolic disease that causes high blood glucose levels, and obesity is a medical condition characterized by an excessive accumulation of body fat that can negatively impact health. Ischemic heart disease drugs are often used in individuals with obesity and diabetes to manage cardiovascular risk factors such as hypertension and dyslipidemia, mitigating the risk of ischemic heart disease. For instance, in 2022, according to the World Obesity Federation, the UK-based Federation that drives global efforts to reduce, prevent, and treat obesity, one billion people globally, including 1 in 5 women and 1 in 7 men, will be living with obesity by 2030. For instance, in June 2024, according to the National Health Service, a UK-based government department, in 2023, the NHS identified over half a million (549,000) additional individuals in England at risk of developing type 2 diabetes, bringing the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330. This represents a significant increase compared to 3,065,825 in 2022, highlighting a rise of nearly 20%. Therefore, the growing prevalence of obesity and diabetes drives the growth of the ischemic heart disease (IHD) drugs market.

Ischemic Heart Disease (IHD) Drugs Market Driver: Rising Heart Failure Cases Drive Surge In Ischemic Heart Disease (IHD) Drugs Market Growth

The increasing incidence of heart failure is expected to propel the growth of the ischemic heart disease (IHD) drug market going forward. Heart failure is a chronic condition in which the heart muscle is unable to pump enough blood to meet the body's needs for blood and oxygen. This can lead to fatigue, shortness of breath, and difficulty performing everyday activities. Ischemic heart disease (IHD) drugs play an important role in the treatment of heart failure. To reduce the risk factors and symptoms of ischemic heart disease, these medications can help avoid heart failure. Ischemic Heart Disease (IHD) drugs inhibit the pacemaker activity of the heart and are beneficial in heart failure patients with reduced ejection fractions and high resting heart rates after a tolerated beta-blocker. For instance, in September 2023, according to the Heart Failure Society of America, a US-based organization, 6.7 million Americans over 20 years of age have heart failure (HF), and the prevalence is expected to rise to 8.5 million Americans by 2030. Therefore, the increasing incidence of heart failure is driving the growth of the ischemic heart disease (IHD) drug market.

Global Ischemic Heart Disease (IHD) Drugs Market Major Players

Major companies operating in the ischemic heart disease (IHD) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC

Global Ischemic Heart Disease (IHD) Drugs Market Trend: Emerging Cardiac Myosin Inhibitors Offer New Therapeutic Potential for Ischemic Heart Disease

Major companies operating in the ischemic heart disease (IHD) drugs market are increasing their focus on developing innovative myosin inhibitor, to gain a competitive edge in the market. A cardiac myosin inhibitor is a drug that reduces myosin activity in the heart muscle, lowering contraction force. It’s beneficial for conditions like hypertrophic cardiomyopathy (HCM), where excessive muscle thickening impairs heart function. For instance, in April 2022, Bristol Myers Squibb, a US-based pharmaceutical company, launched Camzyos (mavacamten). It is the first cardiac myosin inhibitor approved for the treatment of adults with symptomatic new york heart association class ii-iii obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms. The drug works as an allosteric and reversible inhibitor selective for cardiac myosin, reducing hypercontractility, left ventricular hypertrophy, and improving cardiac filling pressures. This helps decrease dynamic left ventricular outflow tract (LVOT) obstruction.

Ischemic Heart Disease (IHD) Drugs Market Merger And Acquisition: Novo Nordisk Strengthens Cardiovascular Portfolio with Acquisition of Cardior Pharmaceuticals

In March 2024, Novo Nordisk, a Denmark-based pharmaceutical company, acquired cardior pharmaceuticals for an undisclosed amount. The acquisition is a significant step in Novo Nordisk's strategy to establish and expand its portfolio in cardiovascular disease, which is a leading cause of mortality worldwide. Cardior pharmaceuticals is a Germany-based pharmaceutical company manufacturing cardiovascular drugs for IHD.

Regional Outlook For The Global Ischemic Heart Disease (IHD) Drugs Market

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (IHD) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ischemic heart disease (IHD) drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ischemic Heart Disease (IHD) Drugs Market?

The ischemic heart disease (IHD) drugs market consists of sales of antiarrhythmic drugs, anticoagulants, anti-anginal medications, nitroglycerin and nitrates, statins, and antiplatelet agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What is the Market Assessment and Strategic Outlook for the Ischemic Heart Disease (IHD) Drugs Industry?

The ischemic heart disease (IHD) drugs market research report is one of a series of new reports from The Business Research Company that provides ischemic heart disease (IHD) drugs market statistics, including ischemic heart disease (IHD) drugs industry global market size, regional shares, competitors with a ischemic heart disease (IHD) drugs market share, detailed ischemic heart disease (IHD) drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ischemic heart disease (IHD) drugs industry. This ischemic heart disease (IHD) drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Ischemic Heart Disease (IHD) Drugs Market Report Forecast Analysis
Report AttributeDetails
Market Size Value In 2025 $6.71 billion
Revenue Forecast In 2034 $7.86 billion
Growth Rate CAGR of 4.0% from 2025 to 2034
Base Year For Estimation 2024
Actual Estimates/Historical Data 2019-2024
Forecast Period 2025 - 2029 - 2034
Market Representation Revenue in USD Billion and CAGR from 2025 to 2034
Segments Covered 1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments: 1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan 6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine 7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain. Additional countries that can be covered in the report are Bangladesh, Thailand, Vietnam, Malaysia, Singapore, Philippines, Hong Kong, New Zealand, Mexico, Chile, Argentina, Colombia, Peru, Austria, Belgium, Denmark, Finland, Ireland, Netherlands, Norway, Portugal, Sweden, Switzerland, Czech Republic, Poland, Romania, Ukraine, Saudi Arabia, Israel, Iran, Turkey, UAE, Egypt, Nigeria, South Africa.
Key Companies Profiled Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC
Customization ScopeRequest for Sample
Pricing And Purchase OptionsExplore Purchase Options

    Table Of Contents

    1. Executive Summary

    2. Ischemic Heart Disease (IHD) Drugs Market Characteristics

    3. Ischemic Heart Disease (IHD) Drugs Market Trends And Strategies

    4. Ischemic Heart Disease (IHD) Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

    5. Global Ischemic Heart Disease (IHD) Drugs Growth Analysis And Strategic Analysis Framework

    5.1. Global Ischemic Heart Disease (IHD) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

    5.2. Analysis Of End Use Industries

    5.3. Global Ischemic Heart Disease (IHD) Drugs Market Growth Rate Analysis

    5.4. Global Ischemic Heart Disease (IHD) Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)

    5.5. Global Ischemic Heart Disease (IHD) Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)

    5.6. Global Ischemic Heart Disease (IHD) Drugs Total Addressable Market (TAM)

    6. Ischemic Heart Disease (IHD) Drugs Market Segmentation

    6.1. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Anti-Dyslipidemic Drugs

    Calcium Channel Blockers

    Beta-Blockers

    Angiotensin-converting enzyme (ACE) Inhibitors

    Angiotensin II Receptor Blockers (ARBs)

    Vasodilators

    Antithrombotic Agents

    6.2. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Angina Pectoris

    Myocardial Infarction

    6.3. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Hospital Pharmacy

    Retail Pharmacy

    Online Pharmacy

    6.4. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Anti-Dyslipidemic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Statins

    Fibrates

    Niacin

    Cholesterol Absorption Inhibitors

    6.5. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Dihydropyridines

    Non-Dihydropyridines

    6.6. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Beta-Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Cardioselective Beta-Blockers

    Non-Selective Beta-Blockers

    Vasodilating Beta-Blockers

    6.7. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Enalapril

    Lisinopril

    Ramipril

    6.8. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Losartan

    Valsartan

    Irbesartan

    6.9. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Nitroglycerin

    Isosorbide Dinitrate

    Hydralazine

    6.10. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    Antiplatelet Drugs

    Anticoagulants

    7. Ischemic Heart Disease (IHD) Drugs Market Regional And Country Analysis

    7.1. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    7.2. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market

    8.1. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market Overview

    Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.3. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    8.4. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    9. China Ischemic Heart Disease (IHD) Drugs Market

    9.1. China Ischemic Heart Disease (IHD) Drugs Market Overview

    9.2. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.3. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    9.4. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

    10. India Ischemic Heart Disease (IHD) Drugs Market

    10.1. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.2. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    10.3. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11. Japan Ischemic Heart Disease (IHD) Drugs Market

    11.1. Japan Ischemic Heart Disease (IHD) Drugs Market Overview

    11.2. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.3. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    11.4. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12. Australia Ischemic Heart Disease (IHD) Drugs Market

    12.1. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.2. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    12.3. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13. Indonesia Ischemic Heart Disease (IHD) Drugs Market

    13.1. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.2. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    13.3. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14. South Korea Ischemic Heart Disease (IHD) Drugs Market

    14.1. South Korea Ischemic Heart Disease (IHD) Drugs Market Overview

    14.2. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.3. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    14.4. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15. Western Europe Ischemic Heart Disease (IHD) Drugs Market

    15.1. Western Europe Ischemic Heart Disease (IHD) Drugs Market Overview

    15.2. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.3. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    15.4. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16. UK Ischemic Heart Disease (IHD) Drugs Market

    16.1. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.2. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    16.3. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17. Germany Ischemic Heart Disease (IHD) Drugs Market

    17.1. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.2. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    17.3. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18. France Ischemic Heart Disease (IHD) Drugs Market

    18.1. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.2. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    18.3. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19. Italy Ischemic Heart Disease (IHD) Drugs Market

    19.1. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.2. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    19.3. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20. Spain Ischemic Heart Disease (IHD) Drugs Market

    20.1. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.2. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    20.3. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market

    21.1. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market Overview

    21.2. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.3. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    21.4. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22. Russia Ischemic Heart Disease (IHD) Drugs Market

    22.1. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.2. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    22.3. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23. North America Ischemic Heart Disease (IHD) Drugs Market

    23.1. North America Ischemic Heart Disease (IHD) Drugs Market Overview

    23.2. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.3. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    23.4. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24. USA Ischemic Heart Disease (IHD) Drugs Market

    24.1. USA Ischemic Heart Disease (IHD) Drugs Market Overview

    24.2. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.3. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    24.4. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25. Canada Ischemic Heart Disease (IHD) Drugs Market

    25.1. Canada Ischemic Heart Disease (IHD) Drugs Market Overview

    25.2. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.3. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    25.4. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26. South America Ischemic Heart Disease (IHD) Drugs Market

    26.1. South America Ischemic Heart Disease (IHD) Drugs Market Overview

    26.2. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.3. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    26.4. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27. Brazil Ischemic Heart Disease (IHD) Drugs Market

    27.1. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.2. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    27.3. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28. Middle East Ischemic Heart Disease (IHD) Drugs Market

    28.1. Middle East Ischemic Heart Disease (IHD) Drugs Market Overview

    28.2. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.3. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    28.4. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29. Africa Ischemic Heart Disease (IHD) Drugs Market

    29.1. Africa Ischemic Heart Disease (IHD) Drugs Market Overview

    29.2. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.3. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    29.4. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

    30. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape And Company Profiles

    30.1. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape

    30.2. Ischemic Heart Disease (IHD) Drugs Market Company Profiles

    30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

    30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

    30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

    31. Ischemic Heart Disease (IHD) Drugs Market Other Major And Innovative Companies

    31.1. Novartis AG

    31.2. Sanofi S.A.

    31.3. Bristol-Myers Squibb Company

    31.4. AstraZeneca PLC

    31.5. GSK PLC

    31.6. Eli Lilly and Company

    31.7. Boehringer Ingelheim International GmbH

    31.8. Viatris Inc.

    31.9. Baxter International Inc.

    31.10. Teva Pharmaceutical Industries Ltd.

    31.11. Sandoz Inc.

    31.12. Sun Pharmaceutical Industries Limited

    31.13. Dr. Reddy's Laboratories Ltd.

    31.14. Cipla Limited

    31.15. Lupin Limited

    32. Global Ischemic Heart Disease (IHD) Drugs Market Competitive Benchmarking And Dashboard

    33. Key Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market

    34. Recent Developments In The Ischemic Heart Disease (IHD) Drugs Market

    35. Ischemic Heart Disease (IHD) Drugs Market High Potential Countries, Segments and Strategies

    35.1 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Countries Offering Most New Opportunities

    35.2 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Segments Offering Most New Opportunities

    35.3 Ischemic Heart Disease (IHD) Drugs Market In 2029 - Growth Strategies

    35.3.1 Market Trend Based Strategies

    35.3.2 Competitor Strategies

    36. Appendix

    36.1. Abbreviations

    36.2. Currencies

    36.3. Historic And Forecast Inflation Rates

    36.4. Research Inquiries

    36.5. The Business Research Company

    36.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Table 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Table 3: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 4: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 5: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 6: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Anti-Dyslipidemic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 7: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 8: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Beta-Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 9: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 10: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 11: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 12: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 13: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 14: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 15: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 16: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 17: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 18: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 19: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 20: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 21: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 22: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 23: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 24: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 25: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 26: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 27: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 28: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 29: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 30: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 31: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 32: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 33: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 34: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 35: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 36: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 37: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 38: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 39: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 40: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 41: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 42: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 43: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 44: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 45: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 46: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 47: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 48: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 49: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 50: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 51: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 52: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 53: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 54: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 55: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 56: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 57: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 58: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 59: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 60: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 61: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 62: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 63: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 64: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 65: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 66: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 67: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 68: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 69: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 70: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 71: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 72: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 73: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 74: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 75: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 76: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 77: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 78: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 79: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 80: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Table 81: Pfizer Inc. Financial Performance
  • Table 82: F. Hoffmann-La Roche Ltd. Financial Performance
  • Table 83: Merck & Co. Inc. Financial Performance
  • Table 84: AbbVie Inc. Financial Performance
  • Table 85: Bayer AG Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2019-2024, $ Billion
  • Figure 2: Global Forecast Market Growth, 2024-2029F, 2034F, $ Billion
  • Figure 3: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 4: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 5: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 6: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Anti-Dyslipidemic Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 7: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 8: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Beta-Blockers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 9: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 10: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 11: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 12: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 13: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 14: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 15: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 16: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 17: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 18: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 19: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 20: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 21: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 22: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 23: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 24: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 25: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 26: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 27: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 28: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 29: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 30: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 31: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 32: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 33: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 34: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 35: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 36: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 37: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 38: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 39: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 40: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 41: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 42: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 43: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 44: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 45: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 46: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 47: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 48: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 49: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 50: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 51: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 52: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 53: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 54: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 55: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 56: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 57: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 58: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 59: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 60: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 61: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 62: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 63: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 64: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 65: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 66: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 67: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 68: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 69: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 70: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 71: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 72: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 73: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 74: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 75: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 76: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 77: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 78: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 79: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 80: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Figure 81: Pfizer Inc. Financial Performance
  • Figure 82: F. Hoffmann-La Roche Ltd. Financial Performance
  • Figure 83: Merck & Co. Inc. Financial Performance
  • Figure 84: AbbVie Inc. Financial Performance
  • Figure 85: Bayer AG Financial Performance

The Plasma Fractionation Market Share, Market Size, And Growth Rate 2022

Read More

The Biosimilar Therapeutic Peptides Market Share, Market Size, And Growth Rate 2022

Read More

Global Anticoagulants Market 2022 – Market Opportunities And Strategies

Read More

What Is The Compression Therapy Market Overview In 2022?

Read More

The Business Research Company offers the plasma fractionation market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the oral biologics and biosimilars market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the ophthalmology drugs market research report 2022 with industry size, share, segments and market growth

Read More

The Business Research Company offers the pharmaceuticals market research report 2022 with industry size, share, segments and market growth

Read More

Antiparasitic Drugs Global Market Report 2025 – By Product Type (Anthelmintics, Antiprotozoals, Ectoparasiticide, Other Products), By Treatment (Avermectins, Bezimidazoles, Pyrimidines, Organophosphates, Imidazolesthiazoles), By Route of Administration (Oral, Injectable, Topical), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Congenital Diaphragmatic Hernia Drugs Global Market Report 2025 – By Type (Posterolateral Bochdalek Hernia, Anterior Morgagni Hernia, Hiatal Hernia), By Treatment (Extracorporeal Membrane Oxygenation, Other Treatments), By Diagnosis (Prenatal, Postnatal), By End-User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Complicated Skin And Skin Structure Infections Drugs Global Market Report 2025 – By Active Ingredients (Delafloxacin, Vancomycin, Ceftaroline Fosamil, Linezolid, Other Active Ingredients), By Route of Administration (Oral, Topical, Parenteral), By End User (Hospitals, Homecare, Specialty Clinics, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Otic Drugs Global Market Report 2025 – By Drug Class (Cerumenolytics, Otic Anesthetics, Otic Anti-Infectives, Otic Steroids, Other Drug Class), By Indication (Otitis, Middle Ear Infections, Other Indication), By Route of Administration (Oral, Topical, Injectable, Other Route of Administration), By End-Users (Hospitals, Specialty Clinics, Homecare, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Preeclampsia Drugs Global Market Report 2025 – By Type (Mild Preeclampsia, Severe Preeclampsia), By Treatment (Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication), By Route of Administration (Oral, Parenteral, Other Route of Administration), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels), By End-User (Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Myelodysplastic Syndrome (MDS) Drugs Global Market Report 2025 – By Drug Type (Chemotherapy, Immunomodulatory Drugs), By Route Of Administration (Oral, Parenteral), By Syndrome (Refractory Cytopenia With Multilineage Dysplasia, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts), By End User (Hospitals, Clinics, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Narcotic Drugs Global Market Report 2025 – By Drug (Opium, Heroin, Codeine, Oxycodone, Other Drugs), By Source (Natural, Semi-Synthetic, Synthetic), By Indication (Pain Management, Cough, Diarrhea, Dysentery, Asthma, Other Indications), By Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Focal Segmental Glomerulosclerosis Drugs Global Market Report 2025 – By Type (Losmapimod, SHP-627, Sparsentan, TM-5484, Other Types), By Treatment (Corticosteroids, Immunosuppressive Drugs, Angiotensin Converting Enzymes (ACE) Inhibitors, A.R. Blockers, Diuretics, Other Treatments), By Route of Administration (Oral, Parenteral), By End User (Hospitals, Homecare, Specialty Clinics, Other End Users) – Market Size, Trends, And Global Forecast 2025-2034

View Report

Frequently Asked Questions

What is the definition of the Ischemic Heart Disease (IHD) Drugs market?

Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function. For further insights on the Ischemic Heart Disease (IHD) Drugs market, request a sample here

How will the Ischemic Heart Disease (IHD) Drugs market drivers and restraints affect the market dynamics? What forces will shape the Ischemic Heart Disease (IHD) Drugs industry going forward?

The Ischemic Heart Disease (IHD) Drugs market major growth driver - Rising Prevalence Of Obesity And Diabetes Fuels Expansion Of The Ischemic Heart Disease (IHD) Drugs Market. For further insights on the Ischemic Heart Disease (IHD) Drugs market, request a sample here

What is the forecast market size or the forecast market value of the Ischemic Heart Disease (IHD) Drugs market?

The Ischemic Heart Disease (IHD) Drugs market size has grown strongly in recent years. The ischemic heart disease (IHD) drugs market size has grown strongly in recent years. It will grow from $6.36 billion in 2024 to $6.71 billion in 2025 at a compound annual growth rate (CAGR) of 5.6%. The growth in the historic period can be attributed to rising global prevalence of ischemic heart disease, increased awareness and diagnostics, changes in lifestyle and dietary patterns, government initiatives for cardiovascular health, collaborations for clinical trials, insurance coverage and reimbursement policies. The ischemic heart disease (IHD) drugs market size is expected to see steady growth in the next few years. It will grow to $7.86 billion in 2029 at a compound annual growth rate (CAGR) of 4.0%. The growth in the forecast period can be attributed to aging population trends, personalized medicine approaches, emphasis on cardiovascular prevention, global health policies and initiatives, international research collaborations. Major trends in the forecast period include shift towards precision medicine approaches, focus on novel anti-atherogenic agents, advancements in lipid-lowering therapies, integration of anti-inflammatory agents, development of antithrombotic and antiplatelet drugs. For further insights on the Ischemic Heart Disease (IHD) Drugs market, request a sample here

How is the Ischemic Heart Disease (IHD) Drugs market segmented?

The ischemic heart disease (IHD) drugs market covered in this report is segmented –
1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents
2) By Disease Class: Angina Pectoris, Myocardial Infarction
3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy Subsegments:
1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors
2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines
3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers
4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril
5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan
6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine
7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants For further insights on the Ischemic Heart Disease (IHD) Drugs market, request a sample here

Which region has the largest share of the Ischemic Heart Disease (IHD) Drugs market? What are the other regions covered in the report?

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. For further insights on the Ischemic Heart Disease (IHD) Drugs market, request a sample here.

Who are the major players in the Ischemic Heart Disease (IHD) Drugs market?

Major companies operating in the ischemic heart disease (ihd) drugs market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Baxter International Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Eagle Pharmaceuticals Inc., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., WG Critical Care LLC, Novitium Pharma LLC. For further insights on the Ischemic Heart Disease (IHD) Drugs market, request a sample here.

What are the key trends in the Ischemic Heart Disease (IHD) Drugs market?

Major trends in the Ischemic Heart Disease (IHD) Drugs market include Emerging Cardiac Myosin Inhibitors Offer New Therapeutic Potential for Ischemic Heart Disease. For further insights on the Ischemic Heart Disease (IHD) Drugs market, request a sample here.

What are the major opportunities in the Ischemic Heart Disease (IHD) Drugs market? What are the strategies for the Ischemic Heart Disease (IHD) Drugs market?

For detailed insights on the major opportunities and strategies in the Ischemic Heart Disease (IHD) Drugs market, request a sample here.

How does the Ischemic Heart Disease (IHD) Drugs market relate to the overall economy and other similar markets?

For detailed insights on Ischemic Heart Disease (IHD) Drugs's relation to the overall economy and other similar markets, request a sample here.

What are the latest mergers and acquisitions in the Ischemic Heart Disease (IHD) Drugs industry?

For detailed insights on the mergers and acquisitions in the Ischemic Heart Disease (IHD) Drugs industry, request a sample here.

What are the key dynamics influencing the Ischemic Heart Disease (IHD) Drugs market growth? SWOT analysis of the Ischemic Heart Disease (IHD) Drugs market.

For detailed insights on the key dynamics influencing the Ischemic Heart Disease (IHD) Drugs market growth and SWOT analysis of the Ischemic Heart Disease (IHD) Drugs industry, request a sample here.